Incannex Healthcare Stock Price, News & Analysis
Why is IXHL Stock Up Today?
Company Description
Incannex Healthcare (NASDAQ: ixhl) is a publicly traded drug manufacturers - specialty & generic company in the Pharmaceutical Preparations sector. The company has a market capitalization of $42.9M, ranking #5,767 among all listed U.S. companies by market cap.
ixhl stock has declined 85.4% over the past year. Shares last traded at $2.78.
On a trailing twelve-month basis, Incannex Healthcare reported revenue of $86K with net income of -$46.9M and diluted earnings per share of $-1.35. The company operates at a net profit margin of -54517.4%.
This page provides a comprehensive overview of ixhl stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Incannex Healthcare (ixhl) stock last traded at $2.78, up 13.67% from the previous close. Over the past 12 months, the stock has lost 85.4%. At a market capitalization of $42.9M, ixhl is classified as a micro-cap stock with approximately 14.0M shares outstanding.
Latest News
Incannex Healthcare has 10 recent news articles, with the latest published today. Of the recent coverage, 2 articles coincided with positive price movement and 6 with negative movement. Key topics include partnership, offering, clinical trial, stock split, management. View all ixhl news →
SEC Filings
Incannex Healthcare has filed 5 recent SEC filings, including 4 Form 8-K, 1 Form 424B5. The most recent filing was submitted on March 25, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ixhl SEC filings →
Financial Highlights
Incannex Healthcare generated $86K in revenue over the trailing twelve months, operating income reached -$23.8M (-27661.6% operating margin), and net income was -$46.9M, reflecting a -54517.4% net profit margin. Diluted earnings per share stood at $-1.35. The company generated -$12.5M in operating cash flow. With a current ratio of 2.86, the balance sheet reflects a strong liquidity position.
Upcoming Events
Start DReAMzz dosing
DReAMzz Phase 2 dosing
Nasdaq compliance deadline
Incannex Healthcare has 3 upcoming scheduled events. The next event, "Start DReAMzz dosing", is scheduled for April 1, 2026 (in 6 days). Investors can track these dates to stay informed about potential catalysts that may affect the ixhl stock price.
Short Interest History
Short interest in Incannex Healthcare (ixhl) currently stands at 21.7 million shares, up 29.9% from the previous reporting period, representing 173.5% of the float. Over the past 12 months, short interest has increased by 30096.4%. This high level of short interest suggests significant bearish sentiment among traders.
Days to Cover History
Days to cover for Incannex Healthcare (ixhl) currently stands at 2.9 days, up 23.8% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 182.5% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 2.9 days.
ixhl Company Profile & Sector Positioning
Incannex Healthcare (ixhl) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.
Investors comparing ixhl often look at related companies in the same sector, including Scynexis (SCYX), Aytu Biopharma Inc (AYTU), Cumberland Pharmaceuticals Inc (CPIX), Rockwell Med Inc (RMTI), and DURECT (DRRX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ixhl's relative position within its industry.
Incannex Healthcare (Nasdaq: IXHL) has partnered with the AASM Foundation to sponsor a 2026 Focused Projects Grant for junior investigators in sleep apnea research and joined the Foundation’s Corporate Recognition Program.
Incannex continues advancing IHL-42X — an oral dronabinol/acetazolamide combination — after positive Phase 2 results, FDA Fast Track designation, and initiation of the DReAMzz Phase 2 dose-optimisation study with patient dosing expected within months toward a planned Phase 3 pathway.